Fanconi Anemia
Also known as: FA, Familial Pancytopenia, Constitutional Aplastic Anemia
Fanconi anemia (FA) is a rare genetic disorder characterized by bone marrow failure, physical abnormalities, and an increased risk of certain cancers. It results from defects in a group of proteins responsible for DNA repair, specifically the repair of DNA damage caused by crosslinking agents. The condition typically presents in childhood with symptoms related to bone marrow failure, such as anemia, thrombocytopenia, and leukopenia.
Fanconi anemia is a rare disease where your body can't fix damaged DNA very well. This can cause problems with your blood, like not having enough red blood cells, and can make you more likely to get sick or get cancer. Doctors can help with special treatments like bone marrow transplants.
Signs & Symptoms
- Bone marrow failure (anemia, thrombocytopenia, leukopenia)
- Short stature
- Skeletal abnormalities (e.g., absent or abnormal thumbs, radius)
- Skin pigmentation changes (café-au-lait spots)
- Eye and ear abnormalities
- Kidney abnormalities
- Increased risk of leukemia (acute myeloid leukemia)
- Increased risk of solid tumors (e.g., head and neck cancers, gynecological cancers)
Treatment Options
Hematopoietic Stem Cell Transplantation (HSCT)
HIGHLY EFFECTIVEAndrogens (e.g., Oxymetholone)
MODERATELY EFFECTIVEHematopoietic Growth Factors (e.g., G-CSF, GM-CSF)
SUPPORTIVEBlood Transfusions
SUPPORTIVEGene Therapy
EXPERIMENTALSupportive Care
SUPPORTIVEDiagnosis
- Complete blood count (CBC) to assess for cytopenias
- Bone marrow aspiration and biopsy
- Chromosome breakage test (diepoxybutane (DEB) or mitomycin C (MMC) test) to assess DNA repair capacity
- Genetic testing to identify mutations in FA genes (e.g., FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FANCN, FANCO, FANCP, FANCR, FANCS, FANCT, FANCV, FANCW, FANCX)
History
Fanconi anemia was first described in 1927 by Swiss pediatrician Guido Fanconi. The genetic basis of the disease began to be elucidated in the 1990s with the identification of the first FA genes. Hematopoietic stem cell transplantation emerged as a life-saving treatment option in the late 20th century.
Recent Breakthroughs
Improved Outcomes with Reduced-Intensity Conditioning HSCT
Studies have shown that reduced-intensity conditioning regimens in HSCT for FA patients can reduce the risk of transplant-related complications while maintaining good engraftment and disease control.
Advancements in Gene Therapy for Fanconi Anemia
Research is ongoing to develop gene therapy approaches for FA, with early-phase clinical trials showing promising results in correcting the underlying genetic defect and improving hematopoiesis.
